Reata announced results from the long-term follow up portion of the LARIAT study demonstrating that pulmonary arterial hypertension patients treated with bardoxolone methyl experienced kidney function improvements that were durable for two years and not associated with adverse outcomes.
Disclaimer
Bardoxolone methyl is an investigational drug. Safety and efficacy have not been established by any regulatory agency.